# NG101m Adjuvant Therapy in Glioblastoma Patients

> **NCT04373785** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **NeuGATE Theranostics** · enrollment: 52 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **RADIATION:** Intensity-modulated radiation therapy
- **DRUG:** Temozolomide
- **DRUG:** NG101m

## Key facts

- **NCT ID:** NCT04373785
- **Lead sponsor:** NeuGATE Theranostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-01
- **Primary completion:** 2030-07-30
- **Final completion:** 2030-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373785, "NG101m Adjuvant Therapy in Glioblastoma Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04373785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*